Chardan Capital reiterated their buy rating on shares of The Medicines Company (NASDAQ:MDCO) in a report published on Wednesday. Chardan Capital currently has a $85.00 target price on the stock.

Several other brokerages have also weighed in on MDCO. CIBC set a $50.00 target price on shares of The Medicines in a research report on Tuesday, May 23rd. ValuEngine upgraded shares of The Medicines from a strong sell rating to a sell rating in a research report on Friday, June 2nd. Citigroup Inc. upped their target price on shares of The Medicines from $43.00 to $45.00 and gave the stock a neutral rating in a research report on Wednesday, July 26th. Jefferies Group LLC restated a buy rating and set a $62.00 target price on shares of The Medicines in a research report on Wednesday, June 28th. Finally, Cowen and Company restated a buy rating and set a $54.00 target price (down from $61.00) on shares of The Medicines in a research report on Thursday, August 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $54.00.

The Medicines (NASDAQ:MDCO) opened at 35.44 on Wednesday. The company has a 50-day moving average of $36.16 and a 200-day moving average of $42.45. The stock’s market capitalization is $2.55 billion. The Medicines has a 52 week low of $30.80 and a 52 week high of $55.95.

The Medicines (NASDAQ:MDCO) last issued its earnings results on Wednesday, August 9th. The company reported ($5.52) earnings per share for the quarter, missing the consensus estimate of ($1.29) by ($4.23). The Medicines had a negative return on equity of 137.20% and a negative net margin of 670.46%. The company had revenue of $18.74 million for the quarter, compared to analyst estimates of $29.64 million. During the same quarter in the previous year, the company posted ($0.62) earnings per share. The company’s quarterly revenue was down 65.8% compared to the same quarter last year. Analysts anticipate that The Medicines will post ($9.69) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Chardan Capital Reaffirms Buy Rating for The Medicines Company (MDCO)” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/09/24/chardan-capital-reaffirms-buy-rating-for-the-medicines-company-mdco.html.

Hedge funds and other institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. lifted its holdings in shares of The Medicines by 341.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,109 shares of the company’s stock valued at $104,000 after purchasing an additional 1,631 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of The Medicines by 5.1% in the first quarter. Envestnet Asset Management Inc. now owns 2,496 shares of the company’s stock valued at $122,000 after purchasing an additional 120 shares in the last quarter. Neuburgh Advisers LLC lifted its holdings in shares of The Medicines by 12.4% in the first quarter. Neuburgh Advisers LLC now owns 2,596 shares of the company’s stock valued at $127,000 after purchasing an additional 286 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of The Medicines by 10.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock valued at $105,000 after purchasing an additional 264 shares in the last quarter. Finally, US Bancorp DE lifted its holdings in shares of The Medicines by 1.7% in the first quarter. US Bancorp DE now owns 3,413 shares of the company’s stock valued at $167,000 after purchasing an additional 58 shares in the last quarter.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Analyst Recommendations for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.